imBio
Minneapolis, US · Michigan LLC · 1 known investors
Find your way into imBio
Sign up to see every warm intro you have to imBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the imBio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Imbio provides analytical software that extracts quantitative lung function data from standard X-ray scans to support non-invasive diagnosis and treatment planning for clinicians. Its technology is applied to conditions such as breathing disorders among veterans exposed to toxic substances, enabled by the PACT Act for treatment at VA hospitals.
Founders & leadership

Investors · 1
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 1 round · 2015
▶$1.1MraisedSep 2015 · 1 investors · Other TechnologyRule 506(b)
- Alnawaz Rehemtulla, M.D.Director
- David HannesExecutive Officer
- Troy D. KopischkeExecutive Officer, Director
- Cynthia MaierExecutive Officer, Director
- Mark SylvesterExecutive Officer
- Danny J. CunaginExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $1.1M
- First sale
- Jul 2015
- Incorporated
- Limited Liability Company, Michigan
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as imBio.
Non-dilutive funding · 14 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $251.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $166.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $222.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $179.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $150.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $144.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does imBio do?
- Imbio provides analytical software that extracts quantitative lung function data from standard X-ray scans to support non-invasive diagnosis and treatment planning for clinicians. Its technology is applied to conditions such as breathing disorders among veterans exposed to toxic substances, enabled by the PACT Act for treatment at VA hospitals.
- Who are imBio's investors?
- imBio's investors include Seneca Partners.
- How much funding has imBio raised?
- imBio has disclosed $1.1M raised across 1 round.
- Where is imBio headquartered?
- imBio is headquartered in Minneapolis, US.

